EXHIBIT 99.1
RBC Life Sciences®
August 5, 2009
RBC Life Sciences Announces Second Quarter 2009 Results
Irving, Texas (RBC Life Sciences: OTCBB: RBCL) — RBC Life Sciences, Inc., a provider of proprietary nutritional supplements, wound care and pain management products, reported today company-wide net sales of $6.76 million for the quarter ended June, 30, 2009, compared to net sales of $6.89 million for the same quarter last year.
The company also reported net earnings of $277,000, or $0.01 per share, during the second quarter of 2009, compared to net earnings of $276,000, or $0.01 per share, in 2008.
“The current global economic decline has presented its challenges, especially to our international licensees, and was the main cause of the quarterly sales decline” said RBC Life Sciences President and CEO, John W. Price. “Meanwhile, we’re pleased with the progress of our planned expansion of the U.S. and Canadian independent sales market. Continuing the first quarter trend, we more than doubled the number of new Associates during the second quarter of 2009 compared to last year.”
Mr. Price said RBC Life Sciences is entering the second phase of the expansion by rolling out a company-wide rebranding effort encompassing everything from redesigned labeling to new and streamlined product offerings.
At its national convention in August, RBC Life Sciences will unveil a revolutionary, new product that the company believes will become one of its best sellers. Mr. Price said the company also will introduce the ClearPay System, the industry’s first virtually balancing flex compensation plan. The new five-leg compensation plan emphasizes business building by giving Associates 10 ways to earn money without the inherent weaknesses of binary systems.
About RBC Life SciencesRBC Life Sciences develops, manufactures and markets high-quality nutritional supplements and personal care products to a growing population of consumers seeking wellness and a healthy lifestyle. Under its MPM Medical brand, RBC Life Sciences also develops and markets to health care professionals in the United States proprietary prescription and nonprescription products for advanced wound care and pain management. All products are tested for quality assurance in-house, and by outside independent laboratories, to comply with regulations in the U.S. and in more than thirty countries in which the products are distributed. For more information, visit the company's Web site at www.rbclifesciences.com.
The statements above, other than statements of historical fact, may be forward-looking. Actual events will be dependent upon a number of factors and risks including, but not limited to, changes in plans by the Company's management, delays or problems in production, changes in the regulatory process, changes in market trends, and a number of other factors and risks described from time to time in the Company's filings with the Securities and Exchange Commission.
Contacts:
Alan Van Zelfden
RBC Life Sciences
972-893-4050
alan.vanzelfden@rbclifesciences.com
Steve Brown
RBC Life Sciences
972-893-4000
steve.brown@rbclifesciences.com
RBC Life Sciences Second Quarter 2009
Page 3
| RBC Life Sciences, Inc. | |
| Summary Results of Operations | |
| (in thousands, except per share data) | |
| (unaudited) | |
| | |
| | | Quarters Ended June 30, | |
| | | 2009 | | | 2008 | |
| | | | | | | |
| Net sales | | $ | 6,759 | | | $ | 6,887 | |
| Gross profit | | | 3,521 | | | | 3,697 | |
| Operating profit | | | 508 | | | | 501 | |
| Earnings before income taxes | | | 466 | | | | 456 | |
| Provision for income taxes | | | 189 | | | | 180 | |
| Net earnings | | | 277 | | | | 276 | |
| | | | | | | | | |
| Earnings per share – basic and diluted | | $ | 0.01 | | | $ | 0.01 | |
| | | | | | | | | |
| Weighted average shares outstanding – basic | | | 21,922 | | | | 21,243 | |
| Weighted average shares outstanding – diluted | | | 22,477 | | | | 22,944 | |
| RBC Life Sciences, Inc. | |
| Summary Results of Operations | |
| (in thousands, except per share data) | |
| (unaudited) | |
| | |
| | | Six Months Ended June 30, | |
| | | 2009 | | | 2008 | |
| | | | | | | |
| Net sales | | $ | 12,775 | | | $ | 13,234 | |
| Gross profit | | | 6,660 | | | | 7,199 | |
| Operating profit | | | 347 | | | | 1,112 | |
| Earnings before income taxes | | | 263 | | | | 1,023 | |
| Provision for income taxes | | | 157 | | | | 392 | |
| Net earnings | | | 106 | | | | 631 | |
| | | | | | | | | |
| Earnings per share – basic and diluted | | $ | 0.00 | | | $ | 0.03 | |
| | | | | | | | | |
| Weighted average shares outstanding – basic | | | 21,920 | | | | 21,179 | |
| Weighted average shares outstanding – diluted | | | 22,509 | | | | 22,920 | |
RBC Life Sciences Second Quarter 2009
Page 4
| RBC Life Sciences, Inc. | |
| Condensed Balance Sheets | |
| (in thousands) | |
| (unaudited) | |
| | | June 30, | | | December 31, | |
| | | 2009 | | | 2008 | |
| Assets | | | | | | |
| Cash and cash equivalents | | $ | 4,097 | | | $ | 4,973 | |
| Inventories | | | 5,608 | | | | 5,707 | |
| Other current assets | | | 1,875 | | | | 2,245 | |
| Total current assets | | | 11,580 | | | | 12,925 | |
| Other assets | | | 7,221 | | | | 6,841 | |
| Total assets | | $ | 18,801 | | | $ | 19,766 | |
| | | | | | | | | |
| Liabilities and shareholders’ equity | | | | | | | | |
| Accounts payable and accrued liabilities | | $ | 2,545 | | | $ | 3,228 | |
| Deferred revenue | | | 3,837 | | | | 4,279 | |
| Other current liabilities | | | 150 | | | | 144 | |
| Total current liabilities | | | 6,532 | | | | 7,651 | |
| Other liabilities | | | 2,693 | | | | 2,728 | |
| Shareholders’ equity | | | 9,576 | | | | 9,387 | |
| Total liabilities and shareholders’ equity | | $ | 18,801 | | | $ | 19,766 | |
# # # #
